Overview Of Individualized Chemotherapy In Ovarian Cancer

Ovarian cancer is one of the most common gynecologic malignant tumor and the leading cause of cancer mortality in female reproductive system tumors.There were approximately 225500 new cases of ovarian cancer and more than 140000 women died of the disease every year. Due to the low specificity of symptoms in the initial stages of the disease and the absence of efficient methods for early diagnosis, the majority of ovarian cancer are diagnosis at advanced stage.The initial treatment of advanced ovarian cancer consists of cytoreductive surgery followed by chemotherapy with the combination of paclitaxel and carboplatin. Epithelial ovarian carcinoma is a chemosensitive disease, and 70%-80% of patients will obtain a response with first-line chemotherapy, but most of them will relapse and therefore second line chemotherapy is necessary. Chemotherapy plays an importance role in the treatment of ovarian cancer, but the result is unsatisfactory.There are significant differences between chemosensitivity to drugs in different ovarian neoplasms and Multidrug resistance is common, so clinicians can't distinguish such differences in the traditional way. The development of molecular biology made the apply of chemosensitivity testing more feasible.Developingfrom human tumor clonogenic assay(HTCA) and MTT method to ATP-TCA, such method becomes simple and convenient as well as accurate.On the other hand, the development of molecular target therapy bring new hope and more challenge to ovarian cancer chemotherapy. A systemic literature search in MEDLINE, CNKI was performed. Literature about chemotherapy of ovarian cancer, chemosensitivity testing and target therapy were collected. This review retrospected the development of individualized chemotherapy in ovarian cancer and the current situation,try to summerize the problem in this area and finally find the development direction.